Bioregulators Khavinson bioregulator tetrapeptideNot FDA-approved · research compound

Vesilute

Vesilute Peptide

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

3 mg per injection SubQ 10-20 mg per week split over 2-3 injections

10-20 mg Oral Daily

Vascular tissue regulatorEndothelial gene expression modulator

Vesilute (Lys-Glu-Asp-Trp) is a Khavinson bioregulator tetrapeptide targeting vascular tissue gene expression. It supports endothelial cell function, vascular wall integrity, and cardiovascular protective pathways. Complementary to Cardiogen (cardiac muscle) for comprehensive cardiovascular bioregulatory support.

Quick Start

Route

SubQ injection

Start low

3 mg SubQ

Frequency

10-20 mg per week split over 2-3 injections

Timing

No fasting required

SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

3 mg per injection · SubQ injection · 10-20 mg per week split over 2-3 injections

conservative starter

3 mg per injection

10-20 mg per week split over 2-3 injections

Standard

Bladder Bioregulation (Oral capsule)

10-20 mg · Oral · Daily

anecdotal · community

Synthetic peptide targeting the bladder wall. This is the ORAL capsule dose and is not an injection dose. Oral peptide absorption is poor, so this figure is far higher than the injectable protocol on purpose. Do not inject this amount.

10-20 mg

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Vials in this mix

Syringe size

Target dose

050100u

Draw to

— units

◆

I will split this dose across more than one syringe

◆

How it works

Vesilute modulates gene expression in endothelial cells and vascular smooth muscle, supporting NO synthase expression, vascular wall integrity, and anti-atherogenic pathways.

What to expect

Early

Days 1–7

Days 1-10: Gene changes initiated.

Mid

Weeks 2–4

Weeks 2-8: Vascular gene programs established.

Later

Weeks 4–12

Months: Sustained vascular support.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Exact-molecule abstract evidence. ESearch was run and 3 source-candidate PMIDs were EFetch-checked; no usable exact-molecule abstract sentence was found.

Dose/route: 3 mg per injection; SubQ injection; 10-20 mg per week split over 2-3 injections. No selected live abstract sentence verified this complete regimen.

Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.

Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.

The honest take

◆

Vascular rejuvenation

Bioregulatory gene expression modulation targeting endothelial and vascular smooth muscle cells.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

◆

Pin alone. Vesilute must not share a syringe with anything else, whatever the pharmacology says. PIN ALONE.

Documented together

CardiogenVesilute targets vascular tissue, Cardiogen targets cardiac tissue. Comprehensive CV bioregulatory support. Run in sequence.

BPC-157Vesilute vascular gene expression + BPC-157 angiogenesis/NO. Complementary. Pin separately.

Keep separate

GHK-CuCopper degrades bioregulators.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Very well tolerated

Less common & notes

Monitor blood pressure if on CV medications.

Pharmacokinetics

Illustrative plasma concentration · 2.0 h

Half-life

0.5h

Peak · Tmax

0.05h

Elimination

2.5h

Bioavailability

~100%

SubQ

Duration of action

Weeks to months (epigenetic gene expression changes persist beyond dosing course)

Clearance

Enzymatic degradation (aminopeptidases)

Storage. Standard BAC water 2-8C. 21-28 days.

Regulatory status

Not FDA-approved. Research peptide.

Put it to work

Calculate, log & track

Open Vesilute straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Vesilute in the app →

Go deeper

The guide & community

The complete Vesilute walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community